Avalo's Monthly HS Injection Clears Phase 2 With 43% Response Rate

Avalo's abdakibart hit a 43 percent HiSCR75 response in phase 2 for hidradenitis suppurativa, roughly 17 points above placebo, with a once-monthly dosing option.